<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31647">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01737918</url>
  </required_header>
  <id_info>
    <org_study_id>URGE II</org_study_id>
    <nct_id>NCT01737918</nct_id>
  </id_info>
  <brief_title>Treatment of Urge Urinary Incontinence in Women After Failure of Cesa or Vasa</brief_title>
  <acronym>URGE II</acronym>
  <official_title>Phase 1/2 Study of the Effect of TOT or Solifenacin After Cesa or Vasa on Urge Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universität Köln</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum der Universität Köln</source>
  <oversight_info>
    <authority>Ethical Committee of the University of Köln: Germany</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urge urinary incontinence can be a disorder caused by destroyed pelvic structures. We
      repaired the uteri-sacral ligaments (USL) by cesa or vasa. The study evaluates if
      solifenacin can lead to continence after surgery or if also the pubo-urethral ligaments
      (PUL) need to be repaired.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It was hypothesized that urge urinary incontinence in women is based on the destruction of
      the uteri-sacral ligaments (USL)and the pubourethral ligaments (PUL). In a preliminary study
      (URGE I) we repaired the USL by cesa or vasa. Those patients who are still incontinent after
      cesa and vasa get the repair of the PUL by means of trans-obturator tapes (TOT). That
      treatment is compared to conservative medical treatment. Cross over after completion of
      three months is possible if no continence is achieved.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>cure of incontinence</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement of urge symptoms</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Treatment of Urge Incontinence After Repair of the USL</condition>
  <arm_group>
    <arm_group_label>trans obturatorial tape (TOT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placement of a sub-urethral tape</description>
  </arm_group>
  <arm_group>
    <arm_group_label>solifenacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TOT</intervention_name>
    <arm_group_label>trans obturatorial tape (TOT)</arm_group_label>
    <other_name>trans obturatorial tape</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>solifenacin</intervention_name>
    <arm_group_label>solifenacin</arm_group_label>
    <other_name>VESICUR 10mg per day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  prior vasa or cesa operation as part of the URGE I study

          -  stress urinary incontinence

          -  mixed urinary incontinence

        Exclusion Criteria:

          -  previous urogynecological surgery

          -  avulsion of cesa or vasa tape

          -  pregnancy

          -  neurologic/psychological reasons for incontinence

          -  body weight &gt;100kg

          -  syndrome of dry overactive bladder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wolfram H Jager, PhD</last_name>
    <phone>0049221478</phone>
    <phone_ext>4900</phone_ext>
    <email>wolfram.jaeger@uk-koeln.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Mallmann, PhD</last_name>
    <phone>0049221478</phone>
    <phone_ext>4940</phone_ext>
    <email>peter.mallmann@uk-koeln.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Abt. Beckenbodenchirurgie der Universitäts-Frauenklinik Köln</name>
      <address>
        <city>Köln</city>
        <state>NRW</state>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram H Jager, PhD</last_name>
      <phone>0049221478</phone>
      <phone_ext>4900</phone_ext>
      <email>wolfram.jaeger@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abt. Beckenbodenchirurgie der Universitäts-Frauenklinik Köln</name>
      <address>
        <city>Köln</city>
        <state>NRW</state>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram H Jager, PhD</last_name>
      <phone>0049221478</phone>
      <phone_ext>4900</phone_ext>
      <email>wolfram.jaeger@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Peter Mallmann, PhD</last_name>
      <phone>0049221478</phone>
      <phone_ext>4940</phone_ext>
      <email>peter.mallmann@uk-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Wolfram H Jager, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 20, 2013</lastchanged_date>
  <firstreceived_date>November 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universität Köln</investigator_affiliation>
    <investigator_full_name>Professor Dr. Wolfram Jäger</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>urge urinary incontinence, cesa, vasa, TOT, solifenacin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
